

# Diet-Induced Weight Loss Reduces DNA Damage and Cardiometabolic Risk Factors in Overweight/Obese Women with Polycystic Ovary Syndrome

Nayara Pereira Soares<sup>a</sup> Ana Celly Souza dos Santos<sup>a</sup> Eduardo Caldas Costa<sup>b</sup>  
George Dantas Azevedo<sup>c</sup> Débora Cristina Damasceno<sup>e</sup>  
Ana Paula Trussardi Fayh<sup>d</sup> Telma Maria Araújo Moura Lemos<sup>a</sup>

<sup>a</sup>Department of Clinical and Toxicological, <sup>b</sup>Department of Physical Education, <sup>c</sup>Department of Morphology, and <sup>d</sup>Department of Nutrition, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, and <sup>e</sup>Department of Gynecology and Obstetrics, Botucatu School of Medicine, São Paulo State University, Botucatu, São Paulo, Brazil

## Key Words

Diet · DNA damage · Cardiometabolic risk factors ·  
Overweight · Obesity · Polycystic ovary syndrome

## Abstract

**Aims:** We aimed to investigate the impact of following a diet to induce weight loss (500 kcal deficit per day) over DNA damage and cardiometabolic risk factors in women with overweight/obesity diagnosed with polycystic ovary syndrome (PCOS). **Methods:** A study was conducted in Natal, RN, Brazil selecting overweight/obese (body mass index  $\geq 25$  and  $< 39$  kg/m<sup>2</sup>) women (18–35 years). The levels of DNA damage were assessed by a single cell gel electrophoresis. Repeated 24 h dietary recall questionnaires, anthropometry, biochemical profile and sex hormones were collected at baseline and after 12 weeks of intervention. **Results:** Women exhibiting a decrease in the markers of DNA damage: tail intensity ( $24.35 \pm 5.86$  – pre diet vs.  $17.15 \pm 5.04$  – post-diet;  $p < 0.001$ ) and tail moment ( $20.47 \pm 7.85$  – pre diet vs.  $14.13 \pm 6.29$  – post-diet;  $p < 0.002$ ). Reduction of calorie intake, weight loss, decreased sexual hormone and cardiometabolic markers such as insulin, homeostasis model assessment of insulin resistance and low-density lipoprotein cholesterol were verified. In the multivariate regression analysis, quanti-

tative insulin sensitivity check index and progesterone were responsible for the variation markers in DNA damage before the diet, losing its influence upon diet. **Conclusion:** DNA damage and the impact of cardiometabolic risk factors decreased after the intervention in women with PCOS, indicating the relevance of a nutritional approach in this group of patients.

© 2016 S. Karger AG, Basel

## Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting 6–12% of the referred population [1, 2]. The main features of PCOS include chronic anovulation, hyperandrogenism and altered ovarian morphology [3]. In addition, women with PCOS have an increased prevalence of cardiometabolic risk factors and diabetes [4–6]. Our research group has reported a higher prevalence of central obesity [7], insulin resistance (IR) [8], low-grade chronic inflammation [9], hypertension [10], metabolic syndrome [11] and a worse autonomic cardiac function [12] in women with PCOS compared to healthy women.

It is well established that obesity, which is present in 30–70% of women with PCOS [13, 14], as well as other cardiometabolic risk factors (e.g. IR) are associated with the generation of reactive oxygen species (ROS), which may increase DNA damage [15, 16]. DNA damage occurs through constant exposure to DNA mutagens of exogenous and/or endogenous origin [17], including cell metabolism and inflammatory responses [18]. Previous studies have reported that women with PCOS present higher DNA damage than healthy ovulatory women, suggesting increased genomic instability [19, 20] and an increased risk for developing cancer in this population [21, 22]. Thus, interventions that decrease obesity and reduce the impact of cardiometabolic risk factors may reduce genomic instability and DNA damage.

From a clinical perspective, a healthy diet with moderate weight reduction (5–10%) bring about a decrease in the number of cardiometabolic risk factors in overweight/obese women, which may reduce genomic instability and DNA damage [23, 24]. The Androgen Excess and PCOS Society states that lifestyle modification, including a healthy diet with moderate weight reduction, should be the first-line therapy for overweight/obese women with PCOS [25, 26]. This recommendation is supported by previous investigations, which reported that reducing caloric diet in the setting of adequate nutritional intake and healthy food choices reduces the impact of several cardiometabolic risk factors in overweight/obese women with PCOS [6, 27, 28]. However, to the best of our knowledge, no previous study has investigated the effects of a diet on DNA damage in women with PCOS. Therefore, this study aims at assessing the effects of diet on DNA damage and cardiometabolic risk factors of overweight/obese women with PCOS. Our initial hypothesis is that diet can play a role in improving the standard of food intake reducing weight and in bringing about a decrease in the number of cardiometabolic risk factors, which in turn would reduce the DNA damage.

## Material and Methods

### *Subjects and Study Design*

Overweight and obese (body mass index (BMI)  $\geq 25$  and  $< 39$  kg/m<sup>2</sup>) women with PCOS, aged from 18 to 35, were eligible for this trial. Thirty-five patients were selected from the Januário Cicco Maternity Hospital of the Federal University of Rio Grande do Norte, Natal, RN, Brazil. The diagnosis of PCOS was made according to the Rotterdam ESHRE-ASRM-sponsored PCOS criteria [3] by 2 independent endocrinologists. Patients diagnosed with other disorders, such as type 2 diabetes, non-classical congenital adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia as well

as patients with renal or hepatic dysfunction or use of medications known to affect reproduction, cardiovascular and/or metabolic function within 90 days of study entry were excluded. This study was approved by the Institutional Ethics Committee and all subjects gave their written informed consent. All patients participated in a 12-week diet intervention program. At baseline and after 12 weeks, the following parameters were analyzed: weight, habitual dietary intake, weight, waist circumference (WC), hormonal and biochemical parameters and DNA damage levels. At study entry, all women were oriented to maintain their habits, especially regarding the physical activity (none of them was involved in a regular physical activity program).

### *Dietary Intervention*

Each participant's energy needs were calculated and adjusted to generate a 500-kcal deficit per day [29, 30]. Dietary characteristics included 15% energy from protein, 60% from carbohydrates (8% simple sugar) and 25% from fat (7% saturated fat) with macronutrient composition calculated as a percentage of the total calories and with a consumption of 25 g/day of fibers. An amount of 400 g/day of fruits and vegetables was ingested by patients. Cereals, roots and tubers, milk and dairy products, meat and eggs, with a low supply of saturated fats, cholesterol and refined grains, were recommended [31, 32]. Diets were supervised by a dietitian and delivered together with a list of healthy food, seasonal shopping lists, meal plans, and recipes. Every 2 weeks, patients returned to measure body weight and, if necessary, adjustments were made to the diet to improve compliance. Energy and macronutrient intake were evaluated using 24 h dietary recalls (2R24h) prior to the diet intervention and post-diet. Food intake based on the information obtained with the 24hR was calculated using software Virtual Nutri Plus<sup>®</sup>, version 2014.

### *Anthropometric*

Patients were submitted to a clinical examination before and after the dietary intervention period. The following anthropometric parameters were assessed: height (m), weight (kg), and WC (cm). WC was measured after expiration, with tape not extensible at the midpoint between the tenth rib and the iliac crest. BMI was calculated as current weight (kg) divided by squared height (m), according to World Health Organization [33].

### *Biochemical and Hormonal Parameters*

Peripheral blood samples were obtained after overnight fasting. The metabolic profile included fasting glucose, triglycerides, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels. All biochemical assays were determined using commercial kits (Diagnostic Labtest – SA<sup>®</sup>, São Paulo, Brazil) by the colorimetric method/enzyme in equipment Bioplus 2000 (Bioplus<sup>®</sup>, Barueri, São Paulo State, Brazil). LDL-cholesterol was calculated following Friedewald's formula [34]: LDL = total cholesterol – HDL-C – (triglycerides/5). The results are expressed as mg/dl.

Follicle stimulating hormone (FSH), progesterone, testosterone, sex hormone binding globulin (SHBG), and insulin were assessed by chemiluminescence (Immulin 1000<sup>®</sup>, Diagnostic Products Corporation, Los Angeles, Calif., USA). IR was calculated by the homeostasis model assessment of IR (HOMA-IR): fasting insulin ( $\mu$ IU/ml)  $\times$  fasting glucose (mmol/l)/22.5 and the quantitative insulin sensitivity check index (QUICKI), QUICKI =  $1/(\log \text{insulin } (\mu\text{IU/ml}) + \log \text{glycemia } (\text{mg/dl}))$  [35].

### DNA Damage Analysis

DNA damage was analyzed for single-cell gel electrophoresis according to Gontijo and Ticer [36]. A volume of 10 ml peripheral blood was mixed with 100 µl of 0.5% low melting point agarose at 37°C, layered on slides precoated with normal melting point agarose and immediately covered with a coverslip. The slides were allowed to cool at 4°C for 5 min to solidify the agarose. The slides were gently removed and immersed in a freshly prepared solution of ice-cold lysis (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% Triton X-100 and 10% dimethyl sulfoxide added immediately before use) to lyse cells and to allow the DNA to unfold. After 1 h in the dark at 4°C, slides were briefly rinsed in phosphate-buffered saline and placed in a horizontal electrophoresis unit, filled with fresh alkaline electrophoresis buffer (300 mM NaOH and 1 mM EDTA pH >13). Electrophoresis was conducted at 4°C for 20 min at 25 V and 300 mA. The slides were neutralized in a buffer (0.4 M Tris pH 7.5). The dry analytical microscope slides were stained with ethidium bromide (20 g/ml in distilled H<sub>2</sub>O; 50 liter/blade), covered with a coverslip before analysis in a Zeiss fluorescence microscope. The microscope was connected to a device charge coupling and a personal computer for analysis system (Comet Assay II Perceptive Instruments, UK) to determine the extent of DNA damage. Results were expressed as a percentage of DNA in the tail (tail DNA fraction divided by the amount of DNA in the cell, multiplied by 100 – intensity tail – tail%), tail moment (tail product and the mean distance of migration in tail arbitrary units), and the tail length (distance from the medium or the perimeter of the head estimated to last visible comet tail signal (m)) [37]. Hundred cells randomly selected (50 of each of the 2 replicate slides) were marked by a blood sample.

### Statistical Analyses


Results are presented as mean, SD, and 95% CI or as median and interquartile range (25th–75th percentiles). Data were tested for normality using the Shapiro–Wilk test. Comparisons between baselines and post-intervention were performed using paired t test and Wilcoxon signed-rank test for parametric and nonparametric analyses, respectively.

In order to evaluate the relationship between components of the diet, risk metabolic factors and variation of DNA damage, correlation tests of Pearson and Spearman were respectively conducted for assessing the parametric and nonparametric variables. In addition, the associations of DNA damage and risk metabolic factors with PCOS were measured by multivariate linear regression with variables with p values <0.20 in the previous association tests. The model was considered significant when it presented all the explanatory variables with p < 0.05.

The effect size (EZ) was calculated using Cohen's d: small effect = 0.2; medium effect = 0.5; large effect = 0.8 [38]. Data were analyzed using SPSS® (Statistical Package for the Social Sciences) version 20.0 for Windows (SPSS, Inc., Chicago, Ill., USA). For the post hoc power analysis, the G\*Power 3.0.10 for Windows was performed.

## Results

Figure 1 shows the patient's recruitment flow diagram. Twenty-two volunteers ( $26 \pm 6.0$  years of age,  $1.56 \pm 6$  cm height) completed the study.



**Fig. 1.** Flow diagram schematically representing the design of this study.

Dietary intake baseline and post-diet of the patients is shown in table 1. After a 12-week intervention, the self-reported 24-hour caloric intake was significantly reduced by  $675 \pm 440$  kcal/day, with reduced consumption of carbohydrates ( $106.9 \pm 25.6$  g/day), proteins ( $20 \pm 5.6$  g/day), total fat ( $25.7 \pm 5.6$  g/day), consumption of saturated fats ( $21.1 \pm 2.7$  g/day), cholesterol level ( $147.2 \pm 90.3$  g/day), and sodium ( $792 \pm 671.4$  mg/day). Increased consumption of fiber ( $5.6 \pm 9.5$  g/day) and mono ( $3.6 \pm 2.4$ ) and polyunsaturated fats ( $2.4 \pm 4.4$  g/day) was also verified. The levels of vitamins A, C and E were adjusted to the reference values recommended by dietary reference intakes [29].

Table 2 shows the effect of diet intervention on anthropometric, hormonal, and biochemical parameters. The weight loss of 3.5% (~2 kg) was related with significant reduction in BMI, FSH, testosterone and SHBG levels and increase in progesterone. A reduction of fasting blood glucose and plasma insulin, HOMA-IR and an increase in QUICK were also noted. However, there were no significant changes in WC, triglyceride and HDL-cholesterol levels.

A decrease in DNA damage markers was observed after the diet intervention (fig. 2). Tail intensity ( $24.3 \pm 5.9$  vs.  $17.1 \pm 5.0\%$ ) and tail moment ( $20.5 \pm 7.8$  vs.  $14.1 \pm 6.3$  UA) decreased after intervention ( $p < 0.01$ ) with a large ES (Cohen's d >0.8), while tail length showed a trend to decrease ( $208.4 \pm 45.9$  vs.  $185.7 \pm 40.5$  µm;  $p = 0.07$ ).

A post hoc statistical power analysis (2-tailed) for the difference between baseline vs. post-intervention was conducted to determine the achieved power of the Wilcoxon signed-rank test, based on the investigated sample size ( $n = 22$ ) for the DNA damage parameters. In this line, tail intensity and tail moment, as parameters of DNA damage, presented improvements after intervention.

**Table 1.** Dietary intake assessed before and at the end of the total 12-week dietary intervention in overweight and obese patients with polycystic ovary syndrome

| Nutrient                            | PCOS women (n = 22) | Baseline (week 0) | Post-diet (week 12) | p value* |
|-------------------------------------|---------------------|-------------------|---------------------|----------|
| Total energy, kcal/day              |                     | 2,076.2±503.8     | 1,401.2±264         | 0.001    |
| Daily intakes (% energy), AMDR      |                     |                   |                     |          |
| Protein                             | 10–35               | 15.2±1.3          | 29.1±3              | 0.001    |
| Carbohydrate                        | 45–65               | 60.2±2.6          | 50.2±4.4            | 0.001    |
| Total fat                           | 20–35               | 24.6±2.1          | 20.7±1.9            | 0.001    |
| <i>Daily intakes (RDA/AI), days</i> |                     |                   |                     |          |
| Protein, g                          | 46                  | 82.7±7.3          | 62.7±6.36           | 0.001    |
| Carbohydrate, g                     | 130                 | 284.6±18.25       | 177.7±37.9          | 0.001    |
| Total dietary fiber, g              | 25                  | 17.5±7.86         | 19.1±8.04           | 0.322    |
| Total fat, g                        | –                   | 67.7±23.6         | 42.3±17.22          | 0.001    |
| Saturated fat, g                    | –                   | 19±6.7            | 12.71±2.24          | 0.001    |
| Monounsaturated fat, g              | –                   | 11.1±3.3          | 14.7±5.32           | 0.003    |
| Polyunsaturated fat, g              | –                   | 8.9±1.4           | 11.2±5.20           | 0.001    |
| Cholesterol, mg                     | –                   | 294.8±164.3       | 147.6±50.9          | 0.001    |
| Sodium, mg                          | 2,300               | 2,073.2±977.3     | 1,281.3±426.7       | 0.001    |
| Vitamin A (RAE), µg                 | 700                 | 581.1±776         | 707.9±755           | 0.884    |
| Vitamin C, mg                       | 75                  | 867±863           | 903.8±717.2         | 0.862    |
| Vitamin E (AT), mg                  | 15                  | 9.3±2.7           | 15.2±3.7            | 0.001    |
| Folate, µg                          | 400                 | 81.3±112          | 88.8±47             | 0.016    |

AMDR = Acceptable macronutrient distribution; RAE = retinol activity equivalents; AT = mg d-α-tocopherol; AI = range.

Data are means ± SD. \* t paired test.


Fonte: Institute of Medicine/Food and Nutrition Board, 2005.

**Table 2.** Baseline and post-diet anthropometric, hormones and metabolic parameters in overweight and obese patients with polycystic ovary syndrome


| PCOS women (n = 22)     | Baseline (week 0) | Post-diet (week 12) | p value <sup>a</sup> |
|-------------------------|-------------------|---------------------|----------------------|
| <b>Anthropometric</b>   |                   |                     |                      |
| Body weight, kg         | 73.3±17.0         | 71.2±16.4           | 0.001                |
| BMI, kg/m <sup>2</sup>  | 29.8±6.1          | 28.9±5.8            | 0.001                |
| WC, cm                  | 95.4±15.8         | 93.2±13.2           | 0.13                 |
| <b>Hormones</b>         |                   |                     |                      |
| FSH, mUI/ml             | 4.0±1.3           | 2.4±0.9             | 0.001                |
| Progesterone, ng/ml     | 0.37 (0.26–0.58)  | 1.89 (1.13–2.42)    | 0.001                |
| SHBG, nmol/l            | 158 (130–187)     | 115 (99–122)        | 0.001                |
| Testosterone, ng/dl     | 140 (113.2–207.7) | 129 (81.4–169.2)    | 0.001                |
| <b>Metabolic</b>        |                   |                     |                      |
| Fasting glucose, mg/dl  | 79±9.6            | 74.6±8.7            | 0.027                |
| Fasting insulin, µIU/ml | 11.3 (8.07–15.07) | 5.5 (4.1–7.6)       | 0.001                |
| HOMA-IR, mol × µU/l     | 1.9 (1.3–3.3)     | 0.9 (0.7–1.3)       | 0.001                |
| QUICK                   | 0.34± 0.03        | 0.38±0.02           | 0.001                |
| Triglycerides, mg/dl    | 123 (63–164)      | 94 (47.5–135)       | 0.385                |
| HDL-cholesterol, mg/dl  | 43.7±13.7         | 46.2±15             | 0.068                |
| LDL-cholesterol, mg/dl  | 89 (70–104)       | 86 (50–50)          | 0.001                |

Data are expressed mean ± SDs or median (25th–75th percentile).

<sup>a</sup> Statistical comparisons were performed by Student t test paired for means and by Wilcoxon test for medians.



**Fig. 2.** Variation of DNA damage markers: tail intensity (a), tail length (b) and tail moment (c) in overweight and obese patients with PCOS (n = 22). Boxplots show median, upper and lower quartiles and minimum and maximum data. The ES was calculated by Cohen's d.



**Fig. 3. a, b** Multiple logistic regression with OR and 95% for overweight and obese patients with PCOS (n = 22), identifying the levels of progesterone and QUICK responsible for the change of DNA damage measured by the tail intensity.

Considering an alpha of 0.05, the achieved power was 0.99 for both tail intensity and tail moment.

In PCOS patients, we found a negative correlation between the change in hormones SHBG ( $r = -0.48$ ,  $p = 0.02$ ) and testosterone ( $r = -0.41$ ,  $p = 0.04$ ) and DNA damage. The other parameters were not significantly associated with the variation of the damage. It was also not possible to identify a significant association between the components of the diet with DNA damage. Multiple logistic regression

identified progesterone level and QUICK that were responsible for 47.5% of the variation of DNA damage measured by tail intensity. The ratios for the corresponding probabilities (95% CI) for QUICK and progesterone were 84.8% (20.17–149) and 6.11% (1.17–11), respectively, before the diet. The same variables did not explain the variation of the DNA damage after the diet. Figure 3 plots the different values of the tail intensity in observed vs. predicted probabilities before and after the diet.

## Discussion

The main findings of our study were that a healthy diet intervention with an average weight loss of 3.5% reduced the DNA damage and impact of cardiometabolic risk factors (mainly IR) in overweight/obese women with PCOS. To the best of our knowledge, this is the first report that shows the positive impact of a healthy diet intervention on genomic instability of an adult female population with increased cardiometabolic risk factors (i.e. women with PCOS).

Effects of diet, weight loss and nutritional factors associated with DNA damage and/or repair processes are inconclusive in the literature. In this sense, our results support the hypothesis that a proper and balanced diet (even with a discrete loss of weight) exerts a protection role on genome, by enhancing DNA repair and/or preventing cell death and mutations as shown in previous studies [24, 39–41].

Some factors might have influenced the reduced DNA damage and the variation in dietary components observed in our study (e.g. reduction of fat and replacement the saturated fat consumption by polyunsaturated, reducing intake carbohydrates or protein), even without any significant association with reduced DNA damage may have influenced the variation of genotoxicity, since levels of DNA damage were correlated with various dietary fat sources and types of dietary fat [42]. In addition, the reduction in the consumption of simple carbohydrates and the increase in consumption of fiber were previously demonstrated to be related to the maintenance of intestinal microbiota, which helps in preventing cancer [43]. Also, the reduction of DNA damage in this study, might reflect the increase in consumption of antioxidants vitamins A, C and E, present in fruits and vegetables, which are associated with the combat of reactive oxygen species, reducing damage to DNA and increasing DNA repair capacity [44–46]. Such increase in the consumption of antioxidants in our study might have generated an improvement in the oxidative balance of patients, since reduced levels of antioxidants have been reported in PCOS women [47]. Together, these results support a beneficial role of proper nutrient intake pattern in generating genome protection in PCOS.

Previous studies reported that PCOS women have increased susceptibility to oxidation of DNA compared to ovulatory healthy women [19, 20, 48, 49], highlighting the importance of conducting clinical practices addressed to minimize the damaging effects caused by the syndrome.

The exact mechanisms related to genomic instability in women with PCOS is uncertain. However, hyperandrogenism, hyperglycemia, and RI with the increased generation of ROS [50, 51] may also be associated with DNA damage, as well as other aspects of genomic instability [52, 53]. Importantly, DNA damage (if not repaired) might result in the initiation of mutagenic and carcinogenic processes [17, 54].

An important finding of our study was the improvement in insulin sensitivity after dietary intervention, since women with PCOS commonly present altered glucose metabolism, increasing the risk of type 2 diabetes [55]. Therefore, the decrease of ~50% of fasting insulin and HOMA-IR observed after dietary intervention was associated with the reduction of DNA damage, which might be related to an attenuated state of oxidative stress, commonly found elevated in PCOS women (regardless of excess weight) [56, 57]. Our results also demonstrated an improvement in the hormonal profile, with reduction of hyperandrogenism, as reported in other studies [58, 59] and even a positive correlation with the reduction of DNA damage. Such a model can be explained by the direct relationship between androgen levels, and increased expression of oxidative protein has been described [60]. In addition, our multivariate model demonstrates, before nutritional intervention, an influence of the level of progesterone and fast in the variation of DNA damage. This influence was reduced after the treatment, suggesting that reducing these risk factors can generate a protective effect to the genome.

Finally, the weight loss associated with a hypocaloric diet adopted by the volunteers could have also contributed to the reduction in DNA damage presented in our results. Overweight, consequently arising from meals rich in fat and high carbohydrate content, acts as a stress factor to promote the proliferation of adipocyte causing overproduction of ROS. Therefore, controlling consumption of nutrients might have resulted in lower ROS production, allowing for a balance in the metabolism and conferring genomic protection [61].

The absence of a control group is the main limitation of our study. Thus, further investigations including a control group are needed.

In conclusion, a healthy diet intervention, even with a modest weight loss, reduced the DNA damage and the impact of cardiometabolic risk factors in overweight/obese women with PCOS, suggesting a genomic protection. These findings reinforce the importance of a healthy diet in clinical management of women with PCOS.

## Acknowledgements

This study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Ministério da Saúde do Brasil, and Fundação de Apoio à Pesquisa do Estado do Rio Grande do Norte. The authors are very grateful to Rafael B. Gelaleti and Aline O. Netto for support in the DNA damage analysis.

## Disclosure statement

The authors have nothing to disclose.

## References

- 1 March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Hum Reprod* 2010;25:544–551.
- 2 Ehrmann DA: Polycystic ovary syndrome. *N Engl J Med* 2005;352:1223–1236.
- 3 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 2004;81:19–25.
- 4 Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, Blackledge H, Khunti K, Howlett TA: Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. *Clin Endocrinol (Oxf)* 2013;78:926–934.
- 5 Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group: Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005;90:66–71.
- 6 Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA: Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. *J Clin Endocrinol Metab* 2010;95:2038–2049.
- 7 Costa EC, Sá JC, Soares EM, Lemos TM, Maranhão TM, Azevedo GD: Anthropometric indices of central obesity how discriminators of metabolic syndrome in Brazilian women with polycystic ovary syndrome. *Gynecol Endocrinol* 2012;28:12–15.
- 8 Pontes AG, Rehme MF, Martins AM, Micussi MT, Maranhão TM, Pimenta Wde P, Pontes A: Insulin resistance in women with polycystic ovary syndrome: relationship with anthropometric and biochemical variables. *Rev Bras Ginecol Obstet* 2012;34:74–79.
- 9 Souza Dos Santos AC, Soares NP, Costa EC, de Sá JC, Azevedo GD, Lemos TM: The impact of body mass on inflammatory markers and insulin resistance in polycystic ovary syndrome. *Gynecol Endocrinol* 2015;31:225–228.
- 10 Azevedo MF, Costa EC, Oliveira AI, Silva IB, Marinho JC, Rodrigues JA, Azevedo GD: [Elevated blood pressure in women with polycystic ovary syndrome: prevalence and associated risk factors]. *Rev Bras Ginecol Obstet* 2011;33:31–36.
- 11 Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão TM: Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. *Fertil Steril* 2008;89:649–655.
- 12 Sá JC, Costa EC, da Silva E, Zuttin RS, da Silva EP, Lemos TM, De Azevedo GD: Analysis of heart rate variability in polycystic ovary syndrome. *Gynecol Endocrinol* 2011;27:443–447.
- 13 Vrbikova J, Hainer V: Obesity and polycystic ovary syndrome. *Obes Facts* 2009;2:26–35.
- 14 Akamine EH, Marçal AC, Camporez JP, Hoshida MS, Caperuto LC, Bevilacqua E, Carvalho CR: Obesity induced by high-fat diet promotes insulin resistance in the ovary. *J Endocrinol* 2010;206:65–74.
- 15 Donmez-Altuntas H, Sahin F, Bayram F, Bitgen N, Mert M, Guclu K, Hamurcu Z, Arbas S, Gundogan K, Diri H: Evaluation of chromosomal damage, cytostasis, cytotoxicity, oxidative DNA damage and their association with body-mass index in obese subjects. *Mutat Res Genet Toxicol Environ Mutagen* 2014;771:30–36.
- 16 Evans MD, Dizdaroglu M, Cooke MS: Oxidative DNA damage and disease: induction, repair and significance. *Mutat Res* 2004;567:1–61.
- 17 Kryston TB, Georgiev AB, Pissis P, Georgakilas AG: Role of oxidative stress and DNA damage in human carcinogenesis. *Mutat Res* 2011;711:193–201.
- 18 Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, Durante-Montiel I, Sánchez-Rivera G, Valadez-Vega C, Morales-González JA: Inflammation, oxidative stress, and obesity. *Int J Mol Sci* 2011;12:3117–3132.
- 19 Moran LJ, Noakes M, Clifton PM, Norman RJ, Fenech MF: Genome instability is increased in lymphocytes of women with polycystic ovary syndrome and is correlated with insulin resistance. *Mutat Res* 2008;639:55–63.
- 20 Dinger Y, Akcay T, Erdem T, Ilker Saygili E, Gundogdu S: DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. *Scand J Clin Lab Invest* 2005;65:721–728.
- 21 Balen A: Polycystic ovary syndrome and cancer. *Hum Reprod Update* 2001;7:522–525.
- 22 Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM; Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group: Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. *Cancer Causes Control* 2010;21:2303–2308.
- 23 Dow CA, Thomson CA, Flatt SW, Sherwood NE, Pakiz B, Rock CL: Predictors of improvement in cardiometabolic risk factors with weight loss in women. *J Am Heart Assoc* 2013;2:e000152.
- 24 Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, Nguyen T, Martin CK, Volaufova J, Most MM, Greenway FL, Smith SR, Deutsch WA, Williamson DA, Ravussin E; Pennington CALERIE Team: Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. *JAMA* 2006;295:1539–1548.
- 25 Moran LJ, Brinkworth G, Noakes M, Norman RJ: Effects of lifestyle modification in polycystic ovarian syndrome. *Reprod Biomed Online* 2006;12:569–578.
- 26 Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society: Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2013;98:4565–4592.
- 27 Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G: Overweight and obese an ovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. *Hum Reprod* 2003;18:1928–1932.
- 28 Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, Frearson M, Thondan M, Stepto N, Teede HJ: Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. *J Acad Nutr Diet* 2013;113:520–545.
- 29 Trumbo P, Schlicker S, Yates AA, Poos M; Food and Nutrition Board of the Institute of Medicine, The National Academies: Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. *J Am Diet Assoc* 2002;102:1621–1630.

- 30 Sociedade Brasileira de Cardiologia, Xavier HT, Izar MC, Faria Neto JR, Assad MH, Rocha VZ, Sposito AC, Fonseca FA, dos Santos JE, Santos RD, Bertolami MC, Faludi AA, Martinez TL, Diamant J, Guimarães A, Forti NA, Moriguchi E, Chagas AC, Coelho OR, Ramires JA: [V Brazilian guidelines on dyslipidemias and prevention of atherosclerosis]. *Arq Bras Cardiol* 2013;101(4 suppl 1):1–20.
- 31 Ministério da Saúde. Secretaria de Atenção à Saúde. Guia Alimentar Para a População Brasileira: Promovendo a Alimentação Saudável (Food Guide for the Brazilian Population), ed 1. Brasília – DF, 2008.
- 32 Margetts B: FAO/WHO launch expert report on diet, nutrition and prevention of chronic diseases. *Public Health Nutr* 2003;6:323–325.
- 33 Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. *World Health Organ Tech Rep Ser* 1995;854:1–452.
- 34 Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.
- 35 Carmina E, Lobo RA: Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. *Fertil Steril* 2004;82:661–665.
- 36 Gontijo AMMC, Ticer R: Teste do cometa para detecção de dano no DNA e reparo em células individualizadas (comet assay for DNA damage detection and repair in individual cells); in Ulbra (ed): *Mutagenese Ambiental*. Canoas (RS), 2003, pp 247–279.
- 37 Speit G, Hartmann A: The comet assay: a sensitive genotoxicity test for the detection of DNA damage. *Methods Mol Biol* 2005;291:85–95.
- 38 Cohen J: *Statistical Power Analysis for the Behavioral Sciences*, ed 2. Hillsdale, Lawrence Earlbaum Associates, 1988.
- 39 Loft S, Velthuis-te Wierik EJ, van den Berg H, Poulsen HE: Energy restriction and oxidative DNA damage in humans. *Cancer Epidemiol Biomarkers Prev* 1995;4:515–519.
- 40 Hofer T, Fontana L, Anton SD, Weiss EP, Villareal D, Malayappan B, Leeuwenburgh C: Long-term effects of caloric restriction or exercise on DNA and RNA oxidation levels in white blood cells and urine in humans. *Rejuvenation Res* 2008;11:793–799.
- 41 Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, Garg R: The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. *J Clin Endocrinol Metab* 2001;86:355–362.
- 42 Bishop KS, Erdich S, Karunasinghe N, Han DY, Zhu S, Jesuthasan A, Ferguson LR: An investigation into the association between DNA damage and dietary fatty acid in men with prostate cancer. *Nutrients* 2015;7:405–422.
- 43 Navarro SD, Mauro MO, Pesarini JR, Ogo FM, Oliveira RJ: Resistant starch: a functional food that prevents DNA damage and chemical carcinogenesis. *Genet Mol Res* 2015;14:1679–1691.
- 44 Gaziev AI, Sologub GR, Fomenko LA, Zaichkina SI, Kosyakova NI, Bradbury RJ: Effect of vitamin-antioxidant micronutrients on the frequency of spontaneous and in vitro gamma-ray-induced micronuclei in lymphocytes of donors: the age factor. *Carcinogenesis* 1996;17:493–499.
- 45 Collins AR, Harrington V, Drew J, Melvin R: Nutritional modulation of DNA repair in a human intervention study. *Carcinogenesis* 2003;24:511–515.
- 46 Mitjavila MT, Fandos M, Salas-Salvadó J, Covas MI, Borrego S, Estruch R, Lamuela-Raventós R, Corella D, Martínez-González MÁ, Sánchez JM, Bulló M, Fitó M, Tormos C, Cerdá C, Casillas R, Moreno JJ, Iradi A, Zaragoza C, Chaves J, Sáez GT: The Mediterranean diet improves the systemic lipid and DNA oxidative damage in metabolic syndrome individuals. A randomized, controlled, trial. *Clin Nutr* 2013;32:172–178.
- 47 Mohamadine AM, Habib FA, Elahi TF: Serum antioxidant vitamins changes in women with polycystic ovary syndrome. *Pathophysiology* 2010;17:189–196.
- 48 Liu J, Zhang D: [The role of oxidative stress in the pathogenesis of polycystic ovary syndrome]. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2012;43:187–190.
- 49 Yesilada E, Sahin I, Ozcan H, Yildirim IH, Yologlu S, Taskapan C: Increased micronucleus frequencies in peripheral blood lymphocytes in women with polycystic ovary syndrome. *Eur J Endocrinol* 2006;154:563–568.
- 50 González F, Rote NS, Minium J, Kirwan JP: Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. *J Clin Endocrinol Metab* 2006;91:336–340.
- 51 Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I: Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. *J Endocrinol Invest* 2012;35:317–321.
- 52 Fenkci V, Fenkci S, Yilmazer M, Serteser M: Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. *Fertil Steril* 2003;80:123–127.
- 53 Sabuncu T, Vural H, Harma M, Harma M: Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. *Clin Biochem* 2001;34:407–413.
- 54 Wang D, Kreutzer DA, Essigmann JM: Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. *Mutat Res* 1998;400:99–115.
- 55 Legro RS, Kunselman AR, Dodson WC, Dunnaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 1999;84:165–169.
- 56 Hyderali BN, Mala K: Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. *Eur J Obstet Gynecol Reprod Biol* 2015;191:15–22.
- 57 Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF: Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. *Hum Reprod Update* 2013;19:268–288.
- 58 Nybacka Å, Carlström K, Ståhle A, Nyrén S, Hellström PM, Hirschberg AL: Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. *Fertil Steril* 2011;96:1508–1513.
- 59 Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;88:812–819.
- 60 González F, Rote NS, Minium J, Kirwan JP: Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. *J Clin Endocrinol Metab* 2006;91:336–340.
- 61 Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer* 2004;4:579–591.